Experimental obesity drug targets appetite through amylin, offering potential alternative to GLP-1 therapies
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept. 28–Oct. 2), and published in The Lancet Diabetes & Endocrinology shows that weekly injections of the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight—generally less weight loss than with existing…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
